XBRANE — Xbrane Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK235.93m
- SEK262.45m
- SEK152.35m
Brief: Xbrane Biopharma Q4 EBITDA SEK -69.2 Million
Brief: Xbrane: Rights Issue Of Units Of About SEK 343 Million
Brief: Xbrane Biopharma Q3 EBITDA SEK -81.6 Million
Brief: Xbrane Biopharma Introduces Cost-Savings Scheme
Brief: Xbrane Biopharma Q2 EBITDA SEK -81.1 Million
Brief: STADA And Xbrane Weigh Options For Ranibizumab Biosimilar Candidate
Brief: Xbrane: U.S. FDA Filing Acceptance For Lucentis (Ranibizumab) Biosimilar Candidate
Brief: Xbrane Biopharma Q1 EPS at SEK -2.12
Brief: Xbrane Carries Out Directed Share Issue, Issue Of Convertible Bonds
Brief: STADA, Xbrane Supply Ximluci® (Ranibizumab) In England Under Nhs Contract
Brief: Xbrane Submits BLA For Ranibizumab Biosimilar Candidate To FDA
Brief: Xbrane Biopharma Q4 EBITDA Loss SEK 50.7 Mln
Brief: STADA And Xbrane Get British Approval For Ximluci (Ranibizumab) Biosimilar Referencing Lucentis
Brief: Xbrane Updates On Ranibizumab Biosimilar Candidate FDA Filing
Brief: Xbrane Biopharma Q3 EBITDA Loss Narrows To SEK 37.6 Mln
Brief: Xbrane, STADA welcome EMA Positive Opinion For Ranibizumab Biosimilar Candidate Ximluci
Brief: Xbrane Biopharma Q2 EBITDA Loss Narrows To SEK 28.4 Mln
Brief: Xbrane Biopharma: Update On Ranibizumab Biosimilar Candidate FDA Filing
Brief: Xbrane Provides Update On Ranibizumab Biosimilar Candidate FDA Filing